BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.: Clinical stage company utilizing AI technology platform to identify improved therapies in neuroscience and immuno-oncology. BXCL501 (sublingual dexmedetomidine): Met primary, key secondary and exploratory endpoints in two pivotal Phase 3 trials for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). NDA submission to FDA planned 1Q21; Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. Data expected 4Q20; BXCL701 (innate immunity activator): Phase 1b/2 ongoing of BXCL701 and KEYTRUDA for Prostate Cancer (tNEPC).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
555 Long Wharf Drive
5th Floor
New Haven, CT 06511
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Vimal Mehta, Dr
BioXcel Therapeutics, Inc., CEO
Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development and corporate fundraising. He is a Co-founder, Chairman of the Board and Chief Executive Officer of BioXcel Corporation. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at Inpharmatica Ltd. and Jubilant Life Sciences. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation. Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in chemistry at the University of Montpellier, France.

Top 10 Holders of BioXcel Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 10.65 1,919,986 101.01 13F 9/30/20
State Street Corp. 7.17 1,293,856 68.07 13F 9/30/20
Artemis Investment Management LLP 5.55 1,001,708 52.70 13F 9/30/20
DNCA Finance SA 3.66 892,453 46.95 Stakes 3/3/20
Vanguard Group, Inc. (Subfiler) 4.60 829,760 43.65 13F 9/30/20
The Vanguard Group, Inc. 4.15 753,588 39.65 Funds 11/30/20
Citadel LP 4.16 749,621 39.44 13F 9/30/20
Victory Capital Management, Inc. (Investment Management) 3.30 594,294 31.27 13F 9/30/20
AllianceBernstein LP 3.27 590,285 31.05 13F 9/30/20
Logos Global Management LP 3.05 550,000 28.94 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.